Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
1. ARVN and PFE announced Phase 3 VERITAC-2 trial results for vepdegestrant. 2. The trial met its primary endpoint for estrogen receptor 1-mutant patients. 3. Overall survival results are not mature yet & will be assessed further. 4. ARVN's stock down 52.4% at $8.35 post-announcement. 5. FDA granted Fast Track designation for vepdegestrant earlier this year.